FT576 in Subjects With Multiple Myeloma
← catalyst calendarSponsored by Fate Therapeutics (industry) · FATE — their whole pipeline →.
Phase
Phase 1
Status
Completed
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
31actual
Sites
14
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-09-02
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2021-11-10 | actual | When the study began enrolling |
| Primary completion | 2024-09-20 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2024-10-18 | actual | The whole study's end, after follow-up |
| First posted | 2022-01-10 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-12-12 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Multiple Myeloma
- Myeloma
Interventions
- Drug: FT576 (Allogenic CAR NK cells with BCMA expression)
- Drug: Cyclophosphamide
- Drug: Fludarabine
- Drug: Daratumumab — also filed as Darzalex, Darzalex Faspro
- Drug: Bendamustine — also filed as Bendeka, Treanda
Primary outcomes
what the primary-completion date above is the date OFIncidence and nature of DLTs within each dose-escalation cohort to determine the MTD or MAD
measured Cycle 1 Day -5 to Day 29 for Regimen A and A1; Cycle 1 Day -11 to Day 29 (each cycle is 40 days) for Regimen B and B1
Determine the RP2D which will be based on the overall safety and anti-tumor activity among the dose escalation and dose expansion cohorts
measured From FPI to LPI's end of Cycle 1 study treatment (End of cycle is Day 29 from Day 1 FT576 infusion)
Incidence, nature, and severity of adverse events
measured Cycle 1 Day -5 to Day 29 for Regimen A and A1; Cycle 1 Day -11 to Day 29 (each cycle is 40 days) for Regimen B and B1
Related
FATE · their whole pipeline · Multiple Myeloma readouts
FATE's other studiesmost recently updated first
- FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors Phase 1 · Recruiting
- A Phase 2, Open-Label, Single-Arm Trial of FT819 in Participants With Lupus Nephritis Phase 2 · Recruiting
- FT839 in Autoimmune Diseases Phase 1/2 · Recruiting
- A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease Phase 1 · Recruiting
- FT819 in Subjects With B-cell Malignancies Phase 1 · Active, not recruiting
Permalink · FATE's whole pipeline · Catalyst calendar · Every registered study · What changed